Pouchitis: Clinical Trials

50 trials for Pouchitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 10 unknown, 7 recruiting, 7 terminated. 15 Phase 2, 12 Not applicable, 7 Phase 3, 6 Phase 1, 6 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 215Terminated 6, Completed 5, Recruiting 2, Suspended 1, Unknown 1
Not applicable12Unknown 5, Completed 4, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 37Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1
Phase 16Terminated 2, Completed 1, Recruiting 1, Unknown 1, Withdrawn 1
Phase 46Recruiting 3, Not yet recruiting 2, Completed 1
Early Phase 13Completed 1, Not yet recruiting 1, Recruiting 1

Follow Pouchitis: new trials by email Literature Review of Pouchitis trials Research Report on Pouchitis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery
5-ASA, Placebo - Ulcerative Colitis (UC), Pouchitis
Phase 4Not yet recruitingUniversity Hospital, Linkoeping1102027-04-012026-08-19
Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC)
MTB-targeted phage therapy - Pouchitis, UC - Ulcerative Colitis
Early Phase 1Not yet recruitingJinling Hospital, China122027-01-012026-10-22
Emerging Indications for Hyperbaric Oxygen Treatment
Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis
Phase 4Not yet recruitingJay C. Buckey Jr.1002026-11-012026-09-09
Etrasimod as Prevention of Pouchitis
etrasimod, Placebo - Pouchitis
Phase 2RecruitingMaia Kayal402026-07-012026-09-21
CLF065 for Chronic Pouchitis
CLF065, Placebo - Pouchitis
Phase 2SuspendedCalibr, a division of Scripps Research202026-06-012026-07-09
GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis
Guselkumab, Diet - Pouchitis
Phase 4RecruitingUniversitaire Ziekenhuizen KU Leuven202026-04-232026-05-05
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC) - Pouchitis, Pouches, Ileoanal
Phase 4RecruitingUniversity of North Carolina, Chapel Hill252025-08-122026-01-30
Exploring the Influence of Trptophan on the Treatment of Pouchitis
Tryptophan 25mg/kg bodyweight, Placebo - Pouchitis
Not applicableNot yet recruitingUniversitätsklinikum Hamburg-Eppendorf202025-04-012025-03-06
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
Vedolizumab, Concomitant Antibiotic Therapy - Pouchitis
Phase 3RecruitingTakeda302024-11-192026-08-03
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
Fecal Microbiota Transplant (FMT) - Chronic Pouchitis, Pouchitis
Early Phase 1RecruitingMaia Kayal162024-10-032026-08-17
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
Intestinal Ultrasound - Ulcerative Colitis, Pouchitis
Not applicableCompletedMayo Clinic662024-07-012026-08-12
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Rifaximin 550 MG Oral Tablet [XIFAXAN] - Pouchitis
Phase 4RecruitingUniversity of North Carolina, Chapel Hill162024-07-012026-10-23
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
EXE-346, Placebo - Ileal Pouch
Phase 1 / Phase 2RecruitingExegi Pharma, LLC502023-11-062026-05-28
Stem Cells for the Treatment of Pouchitis
Mesenchymal Stem Cells (MSCs) - Pouchitis, Crohn's Disease
Phase 1WithdrawnThe Cleveland Clinic2022-04-012026-04-16
Efficacy of Liraglutide Therapy in Patients With IPAA
Liraglutide Pen Injector, Placebo Pen Injector - Pouchitis, Irritable Pouch Syndrome
Phase 2TerminatedUniversity of North Carolina, Chapel Hill82022-03-222024-07-23
Assessment of Patients With Acute Pouchitis Treated With Antibiotics
Observational, No intervention - Pouchitis, Ulcerative Colitis
SuspendedAlimentiv Inc.432021-12-072024-02-20
GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery
GM-CSF, fosfomycin and metronidazole - Pouchitis
Phase 1 / Phase 2UnknownZealand University Hospital182021-09-062023-01-26
Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis
Faecal microbiota transplantation - Pouchitis, Inflammatory Bowel Diseases
Not applicableCompletedOle Thorlacius-Ussing, MD, DMSc, Professor of Surgery32021-03-012022-07-13
Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis
AMT-101 (oral)-Dose A, AMT-101 (oral)-Dose B - Pouchitis
Phase 2CompletedApplied Molecular Transport222021-02-052022-09-14
Tofacitinib For Treatment Of Chronic Pouchitis
Tofacitinib 10 mg - Pouchitis, Ileal Pouchitis
Phase 2TerminatedCedars-Sinai Medical Center62021-01-252024-04-04

Showing 20 of 50. Sign in to see all of them.

Narrower conditions

Colitis, Ulcerative (22)  ·  Crohn Disease (7)  ·  Inflammatory Bowel Diseases (6)  ·  Adenomatous Polyposis Coli (2)  ·  Anastomotic Leak (2)  ·  Colorectal Neoplasms (2)  ·  Calciphylaxis (1)  ·  Cholangitis, Sclerosing (1)  ·  Colitis (1)  ·  Craniocerebral Trauma (1)  ·  Enterocolitis, Pseudomembranous (1)  ·  Epidermolysis Bullosa (1)  ·  Frostbite (1)  ·  Graft vs Host Disease (1)

Broader conditions

Digestive System Diseases (50)  ·  Enteritis (50)  ·  Gastroenteritis (50)  ·  Gastrointestinal Diseases (50)  ·  Ileal Diseases (50)  ·  Intestinal Diseases (50)  ·  Ileitis (49)  ·  Colonic Diseases (22)  ·  Colitis (21)  ·  Inflammatory Bowel Diseases (17)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Postoperative Complications (3)

Interventions

Fecal Microbiota Transplantation (6)  ·  AST 120 (2)  ·  Diet (2)  ·  vedolizumab (2)  ·  Adalimumab (1)  ·  Ciprofloxacin (1)  ·  Clotrimazole (1)  ·  FODMAP Diet (1)  ·  Fosfomycin (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  Hyperbaric Oxygenation (1)  ·  Liraglutide (1)  ·  Medical Marijuana (1)  ·  Metronidazole (1)  ·  Oxygen (1)

Sponsors

University of North Carolina, Chapel Hill (4)  ·  Tel-Aviv Sourasky Medical Center (3)  ·  Charite University, Berlin, Germany (2)  ·  Jinling Hospital, China (2)  ·  Maia Kayal (2)  ·  Mayo Clinic (2)  ·  Ocera Therapeutics (2)  ·  Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery (2)  ·  Takeda (2)  ·  Universitaire Ziekenhuizen KU Leuven (2)  ·  Aalborg University Hospital (1)  ·  Alimentiv Inc. (1)  ·  Applied Molecular Transport (1)  ·  Atlantic Pharmaceuticals Ltd (1)  ·  Boston Medical Center (1)

Countries

United States (24)  ·  Belgium (6)  ·  Canada (6)  ·  Israel (6)  ·  Denmark (5)  ·  Netherlands (5)  ·  France (4)  ·  Germany (4)  ·  Italy (4)  ·  Spain (3)  ·  United Kingdom (3)  ·  China (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  Croatia (1)

Top investigators

Ole Thorlacius-Ussing, Professor (3)  ·  Edward Barnes, MD, MPH (2)  ·  Hans Herfarth, MD, PhD (2)  ·  A. Masclee, Prof MD PhD (1)  ·  Amy L Lightner, MD (1)  ·  Bo Shen, M.D. (1)  ·  Bo Shen, MD (1)  ·  Carl Brown (1)  ·  Chris Dunk (1)  ·  Darrell Pardi, MD (1)  ·  Darrell S. Pardi, MD (1)  ·  Fangyu Wang (1)  ·  Francis Farraye, MD (1)

Results publications

PMID 19415309, PMID 21549404, PMID 21601883, PMID 21983950, PMID 25110406, PMID 32493442, PMID 33501942, PMID 36988594, PMID 38668926, PMID 38708959, PMID 38750870, PMID 39025255, PMID 39485259, PMID 42232317, PMID 42728546

NIH funding

2015 (1), 2023 (1), 2025 (1), R03DK067275 (1), R03DK140415 (1)